Awakn Announces First Patient Screened in Phase 3 Trial of AWKN-001 for Severe Alcohol Use Disorder
About the Trial
The Phase 3 clinical trial, known as MORE (Management of Alcohol use disorder with Ketamine and Optimized Resolution Enhancement), aims to evaluate the effectiveness of AWKN-001, a ketamine-assisted therapy, in treating severe alcohol use disorder.
The trial will enroll approximately 200 patients at multiple sites in North America and Europe.
About AWKN-001
AWKN-001 is a novel treatment approach that combines ketamine with psychotherapy to address the underlying causes of alcohol use disorder.
Ketamine is a dissociative anesthetic that has shown promise in treating depression and other mental health conditions. It is believed to work by blocking a type of brain receptor called the NMDA receptor.
In the MORE trial, AWKN-001 will be administered in conjunction with psychotherapy to help patients develop coping mechanisms and strategies for managing their alcohol use.
Significance of the Trial
Alcohol use disorder is a serious public health problem that affects millions of people worldwide.
There is a significant need for new and effective treatments for alcohol use disorder, as current treatments are often not effective long-term.
The MORE trial is a landmark study that could provide important new evidence on the effectiveness of AWKN-001 in treating severe alcohol use disorder.
About Awakn Life Sciences Corp
Awakn Life Sciences Corp. (NEO: AWKN) is a clinical-stage biotechnology company developing novel therapies for the treatment of addiction.
The company's lead drug candidate, AWKN-001, is a ketamine-assisted therapy for the treatment of alcohol use disorder.
Awakn is headquartered in Toronto, Canada.
Komentar